About a fifth of the agency’s remaining staff was affected, including employees working on special education, funding for low-income students and civil rights enforcement.

An acclaimed researcher is an expert at explaining complicated problems. Now she has to confront the most vexing question: What is happening to her?

The idea that everyone has intrinsic rights to life and liberty was a radical break with millennia of human history. It’s worth preserving.

US president may impose tariffs, demand higher Nato contributions or even declare Norway an enemy, analyst says

A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 diab...

The data shows the steepest decline in August international student arrivals since the pandemic.

North Carolina and Idaho have cut their Medicaid programs to bridge budget gaps, raising fears that providers will stop taking patients and that hospitals will close even before the brunt of a new federal tax-and-budget law takes effect.

Trump administration officials are considering eliminating age as a factor in deciding whether someone is capable of working.

When Senator Wyden stated he’d heard from thousands of doctors and scientists concerned by RFK Jr’s policies, Kennedy responded "I'll put my mailbag against your mailbag any day.” Let's prove Kennedy ...

Prior COVID-19 infection was associated with a 41% increased risk of all-cause dementia.

Those who cite scientific studies to support policies should take care to tell the whole story, especially when it’s complex.

Background Multiple system atrophy (MSA) is a rare, rapidly progressive alpha-synucleinopathy characterized by autonomic dysfunction, parkinsonism and marked cerebellar ataxia, with very limited treatment options. N-acetyl-DL-leucine (ADLL) (Tanganil™), a racemic derivative of leucine is usually well tolerated and has shown promise in improving cerebellar symptoms and reducing REM sleep behavior disorder (RBD), a common non-motor dream-sleep disorder feature of alpha-synucleinopathy. Given this dual potential, we treated three patients with advanced-stage MSA under compassionate use rules. Case presentations Three patients with advanced-stage MSA and severe cerebellar symptoms—two of whom also had moderate RBD—were treated with ADLL (TanganilTM), titrated to 5g/day over 10 days. While both patients with RBD reported self-assessed decrease of RBD symptoms within 2–3 weeks on the full dosage (approximately four weeks after treatment initiation), all three patients had major worsening of gait and balance during the same period, leading to sudden falls and overall health decline. These adverse events prompted early discontinuation of therapy. Gait improved within two weeks after discontinuation of therapy in two patients. In parallel, the RBD phenotype reoccurred. In the third, who had very advanced MSA and concurrent infections, gait only slowly improved over time and it remains unclear whether his worsening of truncal ataxia was attributable to ADLL (TanganilTM), or whether it was related to his concurrent infections with slow recovery. Conclusions While ADLL improved RBD, it was poorly tolerated in these three patients with advanced-stage MSA of predominantly cerebellar type. Further studies are needed to evaluate its safety and efficacy in different, preferably early, stages of MSA.

It's Obamacare health insurance prices — and how much help 24 million Americans will get with their premiums — that are in dispute.